Literature DB >> 23881044

Relationship between oral D-amphetamine self-administration and ratings of subjective effects: do subjective-effects ratings correspond with a progressive-ratio measure of drug-taking behavior?

B Levi Bolin1, Anna R Reynolds, William W Stoops, Craig R Rush.   

Abstract

The abuse potential of drugs has traditionally been determined in humans using subjective ratings of drug effects. However, drug self-administration procedures also provide valuable information about the reinforcing effects of drugs that may contribute to their potential for abuse. Although ratings of subjective effects and drug self-administration data are generally concordant, some divergent findings have been reported. Therefore, the aim of the present analysis was to directly investigate the relationship between the subjective-effects profile and self-administration of oral D-amphetamine in healthy volunteers with a history of stimulant use or abuse, using Pearson's correlational analyses. The results indicated that positive subjective and reinforcing effects significantly increased as a function of D-amphetamine dose. Further, significant, but modest, correlations were observed between ratings of six of 17 total items (Any Effect, High, Like Drug, Good Effects, Willing to Pay For, and Willing to Take Again) and D-amphetamine self-administration under a progressive-ratio schedule of reinforcement. The current findings suggest that, at least under the current set of conditions with oral D-amphetamine, subjective-effects measures and drug self-administration data likely provide different but complimentary information about abuse potential. The most informative findings will thus be obtained from studies that use ratings of subjective effects and drug self-administration methods.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881044      PMCID: PMC4012251          DOI: 10.1097/FBP.0b013e3283645047

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  54 in total

1.  Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans.

Authors:  M Haney; E D Collins; A S Ward; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

2.  Amphetamine, secobarbital, and athletic performance. II. Subjective evaluations of performance, mood states, and physical states.

Authors:  G M SMITH; H K BEECHER
Journal:  J Am Med Assoc       Date:  1960-04-02

3.  Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans.

Authors:  Craig R Rush; William W Stoops; Lon R Hays; Paul E A Glaser; Lon S Hays
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

4.  Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Authors:  Sandra D Comer; James P Zacny; Robert H Dworkin; Dennis C Turk; George E Bigelow; Richard W Foltin; Donald R Jasinski; Edward M Sellers; Edgar H Adams; Robert Balster; Laurie B Burke; Igor Cerny; Robert D Colucci; Edward Cone; Penney Cowan; John T Farrar; David J Haddox; Jennifer A Haythornthwaite; Sharon Hertz; Gary W Jay; Chris-Ellyn Johanson; Roderick Junor; Nathaniel P Katz; Michael Klein; Ernest A Kopecky; Deborah B Leiderman; Michael P McDermott; Charles O'Brien; Alec B O'Connor; Pamela P Palmer; Srinivasa N Raja; Bob A Rappaport; Christine Rauschkolb; Michael C Rowbotham; Cristina Sampaio; Beatrice Setnik; Marta Sokolowska; Joseph W Stauffer; Sharon L Walsh
Journal:  Pain       Date:  2012-09-19       Impact factor: 6.961

5.  Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans.

Authors:  C R Rush; W D Essman; C A Simpson; R W Baker
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

6.  Reinforcing effects of d-amphetamine: influence of novel ratios on a progressive-ratio schedule.

Authors:  Rajkumar J Sevak; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Behav Pharmacol       Date:  2010-12       Impact factor: 2.293

7.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.

Authors:  Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-08-15       Impact factor: 4.492

8.  Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.

Authors:  Manuel Tancer; Chris-Ellyn Johanson
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

9.  Reinforcing and subjective effects of several anorectics in normal human volunteers.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

10.  Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts.

Authors:  L LASAGNA; J M VON FELSINGER; H K BEECHER
Journal:  J Am Med Assoc       Date:  1955-03-19
View more
  10 in total

1.  A Brief Introduction to Human Behavioral Pharmacology: Methods, Design Considerations and Ethics.

Authors:  William W Stoops
Journal:  Perspect Behav Sci       Date:  2022-03-01

2.  Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.

Authors:  B Levi Bolin; William W Stoops; Jeremy P Sites; Craig R Rush
Journal:  J Addict Med       Date:  2016 May-Jun       Impact factor: 3.702

3.  Relationship between intranasal cocaine self-administration and subject-rated effects: predictors of cocaine taking on progressive-ratio schedules.

Authors:  Justin C Strickland; Joshua A Lile; Craig R Rush; William W Stoops
Journal:  Hum Psychopharmacol       Date:  2014-05-19       Impact factor: 1.672

Review 4.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 5.  Opposite regulation of conditioned place preference and intravenous drug self-administration in rodent models: Motivational and non-motivational examples.

Authors:  Thomas A Green; Michael T Bardo
Journal:  Neurosci Biobehav Rev       Date:  2020-06-12       Impact factor: 8.989

6.  Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  J Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.153

7.  Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects.

Authors:  Jian-Feng Liu; Robert Seaman; Justin N Siemian; Rohan Bhimani; Bernard Johnson; Yanan Zhang; Qing Zhu; Marius C Hoener; Jinwoo Park; David M Dietz; Jun-Xu Li
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

8.  Subjective responses predict d-amphetamine choice in healthy volunteers.

Authors:  Conor H Murray; Jingfei Li; Jessica Weafer; Harriet de Wit
Journal:  Pharmacol Biochem Behav       Date:  2021-03-04       Impact factor: 3.533

9.  Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.

Authors:  Jennifer K Hoots; Heather E Webber; Cecilia Nunez; Jessica A Cooper; Paula Lopez-Gamundi; Victoria M Lawlor; Scott D Lane; Michael T Treadway; Margaret C Wardle
Journal:  Psychopharmacology (Berl)       Date:  2021-06-17       Impact factor: 4.415

10.  A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial.

Authors:  Margaret C Wardle; Benjamin A Marcus; Harriet de Wit
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.